ArticleJournal of nucleic acids2017
Selection of DNA Aptamers for Ovarian Cancer Biomarker CA125 Using One-Pot SELEX and High-Throughput Sequencing.
Article in Journal of nucleic acids, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Early-Stage Pancreatic Cancer Diagnosis: Serum Biomarkers and the Potential for Aptamer-Based Biosensors.Molecules (Basel, Switzerland) · 2025Review
- Current developments of SELEX technologies and prospects in the aptamer selection with clinical applications.Journal, genetic engineering & biotechnology · 2024Review
- A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing.Cancer research communications · 2024Article
- Generation of epitope-specific hCG aptamers through a novel targeted selection approach.PloS one · 2024Article
- Bio-SELEX: A Strategy for Biomarkers Isolation Directly from Biological Samples.Methods and protocols · 2023Article
- Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges.Cancers · 2023Review
- Fabrication of mesoporous silica nanoparticles for targeted delivery of sunitinib to ovarian cancer cells.BioImpacts : BI · 2023Article
- Applications of Aptamers in the Diagnosis and Treatment of Ovarian Cancer: Progress From 2016 to 2020.Frontiers in genetics · 2021Review
- Implementation of High-Throughput Sequencing (HTS) in Aptamer Selection Technology.International journal of molecular sciences · 2020Review
- Chemical Modification of Aptamers for Increased Binding Affinity in Diagnostic Applications: Current Status and Future Prospects.International journal of molecular sciences · 2020Review
- Novel ssDNA Ligand Against Ovarian Cancer Biomarker CA125 With Promising Diagnostic Potential.Frontiers in chemistry · 2020Article
- Aptamer-iRNAs as Therapeutics for Cancer Treatment.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Aptamers as Diagnostic Tools in Cancer.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Aptamer Bioinformatics.International journal of molecular sciences · 2017Review
- Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine.International journal of molecular sciences · 2017Review
- Aptamers as the Agent in Decontamination Assays (Apta-Decontamination Assays): From the Environment to the Potential ApplicationJournal of nucleic acids · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
CA125 is a mucin glycoprotein whose concentration in serum correlates with a woman's risk of developing ovarian cancer and also indicates response to therapy in diagnosed patients. Accurate detection of this large, complex protein in patient samples is of great clinical relevance. We suggest that powerful new diagnostic tools may be enabled by the development of nucleic acid aptamers with affinity for CA125. Here, we report on our use of One-Pot SELEX to isolate single-stranded DNA aptamers with affinity for CA125, followed by high-throughput sequencing of the selected oligonucleotides. This data-rich approach, combined with bioinformatics tools, enabled the entire selection process to be characterized. Using fluorescence anisotropy and affinity probe capillary electrophoresis, the binding affinities of four aptamer candidates were evaluated. Two aptamers, CA125_1 and CA125_12, both without primers, were found to bind to clinically relevant concentrations of the protein target. Binding was differently influenced by the presence of Mg
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.